T1	Participants 160 203	intravenously in patients with unresectable
T2	Participants 204 229	pancreatic adenocarcinoma
T3	Participants 243 269	Advanced pancreatic cancer
T4	Participants 686 781	Patients with histological/cytological proven inoperable adenocarcinoma of the head of pancreas
T5	Participants 1063 1088	25 patients were enrolled
